AU2007249225B2 - HLA alleles associated with adverse drug reactions and methods for detecting such - Google Patents

HLA alleles associated with adverse drug reactions and methods for detecting such Download PDF

Info

Publication number
AU2007249225B2
AU2007249225B2 AU2007249225A AU2007249225A AU2007249225B2 AU 2007249225 B2 AU2007249225 B2 AU 2007249225B2 AU 2007249225 A AU2007249225 A AU 2007249225A AU 2007249225 A AU2007249225 A AU 2007249225A AU 2007249225 B2 AU2007249225 B2 AU 2007249225B2
Authority
AU
Australia
Prior art keywords
substituted
hla
heterocyclic
nrs
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007249225A
Other languages
English (en)
Other versions
AU2007249225A1 (en
Inventor
Chi-Feng Chang
Wei-Hsuan Chen
Yuan-Tsong Chen
Shuen-Lu Hung
Hsin-Yu Lin
Chih-Lung Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Pharmigene Inc
Original Assignee
Academia Sinica
Pharmigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007249225(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica, Pharmigene Inc filed Critical Academia Sinica
Publication of AU2007249225A1 publication Critical patent/AU2007249225A1/en
Application granted granted Critical
Publication of AU2007249225B2 publication Critical patent/AU2007249225B2/en
Priority to AU2013219191A priority Critical patent/AU2013219191A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2007249225A 2006-05-11 2007-05-11 HLA alleles associated with adverse drug reactions and methods for detecting such Ceased AU2007249225B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013219191A AU2013219191A1 (en) 2006-05-11 2013-08-21 Hla alleles associated with adverse drug reactions and methods for detecting such

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80012106P 2006-05-11 2006-05-11
US60/800,121 2006-05-11
PCT/US2007/068782 WO2007134235A2 (en) 2006-05-11 2007-05-11 Hla alleles associated with adverse drug reactions and methods for detecting such

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013219191A Division AU2013219191A1 (en) 2006-05-11 2013-08-21 Hla alleles associated with adverse drug reactions and methods for detecting such

Publications (2)

Publication Number Publication Date
AU2007249225A1 AU2007249225A1 (en) 2007-11-22
AU2007249225B2 true AU2007249225B2 (en) 2013-06-27

Family

ID=38694734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007249225A Ceased AU2007249225B2 (en) 2006-05-11 2007-05-11 HLA alleles associated with adverse drug reactions and methods for detecting such

Country Status (17)

Country Link
US (2) US7943309B2 (enExample)
EP (1) EP2016198B1 (enExample)
JP (1) JP2009536828A (enExample)
KR (1) KR101450348B1 (enExample)
CN (1) CN101454462A (enExample)
AU (1) AU2007249225B2 (enExample)
BR (1) BRPI0710436A8 (enExample)
CA (1) CA2651954C (enExample)
DK (1) DK2016198T3 (enExample)
ES (1) ES2422735T3 (enExample)
IL (1) IL194900A (enExample)
MY (1) MY150648A (enExample)
NZ (2) NZ597628A (enExample)
PL (1) PL2016198T3 (enExample)
PT (1) PT2016198E (enExample)
TW (1) TWI335937B (enExample)
WO (1) WO2007134235A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536021A1 (en) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
US8927462B2 (en) 2010-04-12 2015-01-06 Academia Sinica Method for identifying HLA complexes associated with adverse drug reactions
WO2012174723A1 (en) * 2011-06-23 2012-12-27 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung Risk assessment for phenytoin-induced adverse drug reactions
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102660635B (zh) * 2012-01-14 2014-03-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN103114138B (zh) * 2013-01-27 2014-12-03 复旦大学 Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒
CN105722999A (zh) * 2013-09-17 2016-06-29 新加坡科技研究局 检测遗传变体的方法
CN104017898B (zh) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
CN104232781B (zh) * 2014-09-26 2017-04-19 陕西佰美基因股份有限公司 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法
CN106119362B (zh) * 2016-06-30 2019-09-10 江苏伟禾生物科技有限公司 一种用于检测hla-b*1502等位基因的引物组及试剂盒
CN108929902B (zh) * 2018-07-28 2022-03-25 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法
CN109554460B (zh) * 2018-12-17 2022-03-22 上海市疾病预防控制中心 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
US20220259655A1 (en) * 2019-05-06 2022-08-18 Chang Gung Memorial Hospital, Linkou Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
CN111620924A (zh) * 2020-06-04 2020-09-04 华中农业大学 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用
CN113308532A (zh) * 2021-05-28 2021-08-27 上海康黎诊断技术有限公司 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒，以及方法
WO2023080478A1 (ko) * 2021-11-02 2023-05-11 주식회사 랩 지노믹스 Ｈｌａ－ｂ＊5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883238A (en) * 1993-03-18 1999-03-16 N.V. Innogenetics S.A. Process for typing HLA-B using specific primers and probes sets
US20050100926A1 (en) * 2003-11-10 2005-05-12 Yuan-Tsong Chen Risk assessment for adverse drug reactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5550039A (en) 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
BRPI0407569A (pt) * 2003-02-17 2006-02-14 Novartis Ag uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883238A (en) * 1993-03-18 1999-03-16 N.V. Innogenetics S.A. Process for typing HLA-B using specific primers and probes sets
US20050100926A1 (en) * 2003-11-10 2005-05-12 Yuan-Tsong Chen Risk assessment for adverse drug reactions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMMERSON, B.T. et al., Arthritis and Rheumatism, 1988, Vol. 31, No. 3, pages 436-440 *
HAMANAKA, H. et al., Clinical and Experimental Dermatology, 1998, Vol. 23, pages 32-34 *
HUNG et al., PNAS, 2005, Vol. 102, No. 11, pages 4134-4139 *

Also Published As

Publication number Publication date
MY150648A (en) 2014-02-14
ES2422735T3 (es) 2013-09-13
AU2007249225A1 (en) 2007-11-22
WO2007134235A3 (en) 2008-01-17
CA2651954A1 (en) 2007-11-22
EP2016198B1 (en) 2013-05-01
DK2016198T3 (en) 2013-07-15
KR20090031671A (ko) 2009-03-27
IL194900A (en) 2013-02-28
BRPI0710436A8 (pt) 2018-06-26
CN101454462A (zh) 2009-06-10
US20080145846A1 (en) 2008-06-19
WO2007134235A2 (en) 2007-11-22
KR101450348B1 (ko) 2014-10-14
TWI335937B (en) 2011-01-11
CA2651954C (en) 2014-02-25
IL194900A0 (en) 2009-08-03
US20110212439A1 (en) 2011-09-01
NZ572259A (en) 2012-03-30
EP2016198A2 (en) 2009-01-21
PL2016198T3 (pl) 2013-12-31
JP2009536828A (ja) 2009-10-22
PT2016198E (pt) 2013-07-29
BRPI0710436A2 (pt) 2012-10-09
TW200844238A (en) 2008-11-16
US8142999B2 (en) 2012-03-27
NZ597628A (en) 2013-07-26
EP2016198A4 (en) 2010-07-21
US7943309B2 (en) 2011-05-17

Similar Documents

Publication Publication Date Title
AU2007249225B2 (en) HLA alleles associated with adverse drug reactions and methods for detecting such
AU2004289951B2 (en) Risk assessment for adverse drug reactions
Bhanusali et al. PTPN22 profile indicates a novel risk group in Alopecia areata
AU2013219191A1 (en) Hla alleles associated with adverse drug reactions and methods for detecting such
US8236497B2 (en) Methods of diagnosing cardiovascular disease
HK1134325A (en) Hla alleles associated with adverse drug reactions and methods for detecting such
Kekou et al. Facioscapulohumeral muscular dystrophy molecular testing using a non radioactive protocol
Hadžija et al. Association of TNF-α and PTPN22 SNPs with the risk and clinical outcome of type 1 diabetes
冯学兵 et al. Single nucleotide polymorphisms of deoxyribonuclease Ⅰand their expre ssion in Chinese systemic lupus erythematosus patients

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired